�鶹��ý

�鶹��ý served as legal advisor to Shanghai-based research and development company Hansoh Pharmaceutical Group Co, Ltd (“Hansoh Pharma”) in their collaboration with London-based biotechnology company Silence Therapeutics plc, a leader in the discovery, development, and delivery of novel small interfering RNA (siRNA) therapeutics for the treatment of diseases with significant unmet medical need. As part of the collaboration, the companies will develop novel siRNA therapeutics for three undisclosed targets using Silence’s proprietary mRNAi GOLD™ platform.

Under the terms of the agreement, Hansoh Pharma will gain an exclusive option to license rights to the first two targets in Greater China, Hong Kong, Macau, and Taiwan, while Silence will retain the rights in all other territories after the completion of Phase 1 studies. Additionally, Hansoh Pharma will have the exclusive option to license global rights to a third target at the point of investigational new drug (IND) filing and will also take responsibility for all development activities post-option exercise for the third target. Hansoh Pharma will make a $16 million upfront payment, and Silence is eligible to receive up to $1.3 billion in milestones, as well as royalties.

Founded in 1995, Hansoh Pharma is one of the largest biopharmaceutical companies in Greater China and Asia, whose mission is to improve human health through continuous innovation. With over 20 years of research and development (R&D) experience, Hansoh Pharma has fully integrated R&D, manufacturing, and commercial capabilities, supporting leading positions across a broad range of therapeutic areas, including oncology, central nervous system (CNS) disorders, infectious diseases, cardiovascular disease, diabetes, and autoimmune diseases.

The �鶹��ý team was led by Partner Andrew Rawlins and Associate Chloe Talbert.

About �鶹��ý

�鶹��ý looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With approximately 1,100 lawyers in 25 offices across the United States, Mexico, Europe and Asia, �鶹��ý approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.